Recombinant Human UBX domain-containing protein 8 (UBXN8)

What is UBXN8 and what is its primary cellular function?

UBXN8, also known as UBXD6 or REP-8, is a member of the ubiquitin regulatory X (UBX) protein family, which represents the largest known group of p97 cofactors. It is a transmembrane protein localized in the endoplasmic reticulum (ER) membrane that tethers p97, a versatile ATPase complex, to the ER membrane via its UBX domain . This interaction facilitates efficient ER-associated degradation (ERAD) of misfolded proteins . Growing evidence suggests that UBXN8, like several other UBX protein family members, regulates processes associated with oncogenesis, including cell proliferation and apoptosis .

How does UBXN8 interact with the p97 ATPase complex?

UBXN8 contains a UBX domain that specifically recognizes and binds to the N-terminal domain of p97. This interaction is crucial for ERAD function, as it allows UBXN8 to facilitate the sterol-stimulated dislocation of ubiquitylated proteins from the ER membrane to proteasomal degradation . Experimental methods to study this interaction include:

• Co-immunoprecipitation with recombinant human anti-UBXN8 antibodies

• UBX domain mutagenesis studies

• Proximity ligation assays for in situ visualization of the UBXN8-p97 interaction

Research indicates that the association of this cofactor with p97 is essential for ERAD efficiency, and disruption of this interaction leads to accumulation of ERAD substrates .

What techniques are recommended for detecting endogenous UBXN8 expression?

For reliable detection of endogenous UBXN8 expression, researchers should consider:

mRNA detection:

• SYBR Green real-time quantitative PCR (qRT-PCR) with UBXN8-specific primers

• Data analysis using the 2^-ΔΔCt method with GAPDH as internal control

Protein detection:

• Western blot analysis using recombinant human anti-UBXN8 antibodies (e.g., Abcam ab159924)

• Immunohistochemistry for tissue samples

• Flow cytometry for cell population analysis

For complex experiments, CRISPR/Cas9-mediated tagging with fluorescent reporters enables live-cell tracking of UBXN8 .

What role does UBXN8 play in cholesterol biosynthesis regulation?

UBXN8 is an essential determinant of metabolically stimulated degradation of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), a rate-limiting enzyme in cholesterol biosynthesis . The mechanistic process involves:

• In response to oxysterols and intermediates of the mevalonate pathway, UBXN8 facilitates the sterol-stimulated dislocation of ubiquitylated HMGCR from the ER membrane

• This process directs HMGCR to proteasomal degradation, a function dependent on UBXN8's UBX domain

• UBXN8 ablation leads to aberrant cholesterol synthesis due to loss of this feedback control mechanism

This process represents an example of metabolically controlled feedback regulation, where UBXN8 couples flux across the mevalonate pathway to control cholesterol synthesis .

How is UBXN8 involved in cancer progression, particularly in AML?

UBXN8 has been identified as a tumor suppressor in multiple cancer types. In t(8;21) acute myeloid leukemia (AML), UBXN8 is epigenetically silenced by the RUNX1-RUNX1T1 fusion protein . Key findings include:

These findings suggest that targeting UBXN8 expression may represent a potential therapeutic strategy for multiple cancer types, particularly t(8;21) AML .

What experimental models are recommended for studying UBXN8 function in vivo?

Researchers investigating UBXN8 function in vivo should consider these model systems:

Mouse models:

• Xenograft models using human cell lines with modified UBXN8 expression (as demonstrated in AML studies)

• CRISPR/Cas9-generated UBXN8 knockout mice

• Conditional tissue-specific knockout models

Cell line models:

• SKNO-1 and Kasumi-1 cells for AML studies

• HL-60, THP-1, and MV4-11 for comparative AML studies without t(8;21) translocation

• Haploid mammalian cells with mNeon-tagged endogenous HMGCR for cholesterol regulation studies

The xenograft model described in AML research demonstrated that UBXN8 upregulation significantly slowed cell proliferation and promoted cell differentiation in vivo, validating this approach for studying UBXN8's tumor-suppressive functions .

How does the RUNX1-RUNX1T1 fusion protein regulate UBXN8 expression?

The RUNX1-RUNX1T1 fusion protein (resulting from the t(8;21) translocation) regulates UBXN8 expression through epigenetic silencing via a multi-step process:

• The fusion protein directly binds to RUNX1-binding sites in the UBXN8 promoter region

• It recruits chromatin-remodeling enzymes including DNA methyltransferases (DNMT1, DNMT3A, DNMT3B)

• This recruitment leads to methylation of CpG islands in the UBXN8 promoter

• The resulting heterochromatic silencing of UBXN8 contributes to leukemogenesis

Chromatin immunoprecipitation (ChIP) experiments confirm direct binding of RUNX1-RUNX1T1 to the UBXN8 promoter using antibodies against RUNX1 (ab23980; Abcam) and RUNX1T1 (ab195329; Abcam). Treatment with decitabine (1.0 μM for 72h), a DNA methylation inhibitor, upregulates UBXN8 expression in RUNX1-RUNX1T1+ AML cell lines, confirming the methylation-dependent silencing mechanism .

What approaches are recommended for UBXN8 overexpression in cancer cell lines?

For researchers investigating the effects of UBXN8 overexpression in cancer cells, the following methodological approach is recommended:

Lentiviral expression system:

• Utilize lentiviral expression vectors (e.g., Lenti-UBXN8) for ectopic induction

• Transduce cells at appropriate MOI (100 used in AML studies)

• Centrifuge at 1000 × g for 3h with polybrene (5 ng/mL)

• Select with puromycin for stable integration

• Confirm expression via flow cytometry

Functional assays:

• Cell proliferation: CCK-8 assay with 3h incubation at 37°C

• Colony formation: Methylcellulose H4230 culture system (500 cells/mL) for 10 days

• Cell cycle analysis: Propidium iodide staining with flow cytometry detection

This systematic approach provides complementary data on how UBXN8 affects cancer cell behavior and supports evaluation of potential therapeutic applications.

What techniques are effective for investigating UBXN8's interactions with chromatin-remodeling enzymes?

To study UBXN8's interactions with chromatin-remodeling enzymes, especially in the context of epigenetic regulation in cancer, researchers should employ:

Chromatin Immunoprecipitation (ChIP):

• Prepare cross-linked chromatin from approximately 4 × 10^8 cells

• Fragment to ~200 bp by sonication (35 cycles of 30s each) using a Bioruptor sonicator

• Immunoprecipitate with antibodies against specific targets:

  • RUNX1 (ab23980; Abcam)

  • RUNX1T1 (ab195329; Abcam)

  • DNA methyltransferases: DNMT3A (ab2850), DNMT3B (ab2851), DNMT1 (ab92314)

• Use normal mouse IgG as negative control and input DNA (without antibody) as input control

• Amplify regions of interest by SYBR Green qRT-PCR with specific primers

DNA Methylation Analysis:

• MethylC-capture sequencing (MCC-Seq) effectively detects specific methylation patterns in promoter regions

• Bisulfite sequencing for targeted analysis of CpG islands in the UBXN8 promoter

These techniques enable detailed characterization of the epigenetic mechanisms controlling UBXN8 expression in different cellular contexts.

How can researchers evaluate the potential of UBXN8 as a therapeutic target?

To evaluate UBXN8 as a therapeutic target, researchers should employ a multi-phase approach:

Phase 1: Expression correlation with clinical outcomes

• Analyze UBXN8 expression in patient samples using public databases like BloodSpot and Gene Expression Omnibus (GSE13159)

• Correlate expression levels with prognostic indicators and survival data

Phase 2: Mechanism validation

• Test DNA methyltransferase inhibitors (e.g., decitabine at 1.0 μM for 72h) to restore UBXN8 expression

• Evaluate effects on cellular proliferation, differentiation, and apoptosis

Phase 3: In vivo validation

• Establish xenograft models with UBXN8-overexpressing cells

• Monitor tumor growth, differentiation status, and survival

• Assess combination approaches with standard therapies

This systematic approach provides a framework for translating basic UBXN8 research into potential clinical applications for cancer treatment.

What are emerging areas of UBXN8 research beyond cancer and cholesterol regulation?

While UBXN8's roles in cancer biology and cholesterol regulation are established, emerging research suggests broader implications:

Proteasomal degradation pathways:

• UBXN8's potential involvement in degradation of proteins beyond HMGCR

• Role in specific stress-response pathways

Potential in other cancer types:

• Initial studies in triple-negative breast cancer show promise for expanding UBXN8 research beyond AML and HCC

• The UBXD family (UBXDF) of proteins is being investigated across multiple cancer types

Therapeutic targeting strategies:

• Development of small molecules to enhance UBXN8 expression

• Combination approaches with existing therapies like DNA methyltransferase inhibitors

These frontier areas represent opportunities for researchers to make significant contributions to understanding UBXN8 biology.

What technical challenges exist in producing functional recombinant UBXN8 for structural studies?

Researchers working with recombinant UBXN8 face several technical challenges:

Expression challenges:

• UBXN8 is a transmembrane protein, making soluble expression difficult

• Bacterial expression systems often produce misfolded protein

Purification considerations:

• Detergent selection is critical for maintaining native conformation

• Protein stability during purification processes

Recommended approaches:

• Mammalian expression systems for proper post-translational modifications

• Expression of functional domains (e.g., UBX domain) for structural studies

• Fusion tags to enhance solubility while minimizing functional interference

• Native nanodiscs or amphipols for stabilizing membrane domains

Overcoming these challenges is essential for detailed structural characterization of UBXN8 and its interactions with binding partners.

How might single-cell approaches advance our understanding of UBXN8 expression heterogeneity?

Single-cell technologies offer promising avenues to explore UBXN8 expression heterogeneity:

Single-cell RNA sequencing:

• Characterize UBXN8 expression variance within tumor populations

• Identify specific cell subpopulations where UBXN8 expression is particularly relevant

• Correlate with differentiation states and cell cycle phases

Single-cell proteomics:

• Quantify UBXN8 protein levels at single-cell resolution

• Map protein-protein interaction networks in individual cells

Spatial transcriptomics:

• Analyze UBXN8 expression patterns within the tumor microenvironment

• Correlate with histopathological features

These approaches could reveal previously unappreciated roles of UBXN8 in specific cellular contexts and tumor microenvironments, potentially identifying new therapeutic opportunities.